Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
about
Body fluid identification by mass spectrometry.Azacytidine induces necrosis of multiple myeloma cells through oxidative stress.Cancer-testis antigens: the current status on antigen regulation and potential clinical use.Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
P2860
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@en
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@nl
type
label
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@en
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@nl
prefLabel
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@en
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@nl
P2093
P2860
P1433
P1476
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
@en
P2093
Benjamin Farmer
Jian Zhang
Seah H Lim
Yana Zhang
Zhiqing Wang
P2860
P304
P356
10.1016/J.LEUKRES.2008.03.036
P577
2008-05-12T00:00:00Z